such as PARP inhibitors. Synthetic lethality is frequently induced in cells with reduced repair function (chemotherapy sensitivity).
Consequently, HBOC patients are highly sensitive to DNA-damaging agents such as PARP inhibitor, platinum-based agents, and topoisomerase inhibitors. 6 In synthetic lethality theory, cells survive even if one of two specific genes involved in cell survival is inhibited. However, cell death is induced when two genes are simultaneously repressed. Poly(ADP-ribose) polymerase inhibitor treatment is a novel therapy for HBOC patients that targets BRCA1/2 mutations as well as PARP. 7, 8 This Normal cells mainly repair DSB by two mechanisms during the cell cycle: HR and NHEJ. 9 Optimum pathway selection is necessary for DSB repair under specific conditions. Although NHEJ repairs DSB throughout the cell cycle, HR only functions in the S/G2 phase following DNA replication. [10] [11] [12] [13] Many reports have investigated the mechanism of "DSB repair pathway choice" in the S/G2 phase where NHEJ overlaps with HR. Understanding of this pathway choice may best explain how PARP inhibitor-induced DSB in S-phase is repaired in several situations.
In the present review, we summarize our current knowledge on the synthetic lethality between BRCA1/2 dysfunction and PARP inhibitors focusing on the molecular mechanisms that regulate the two major DSB repair pathways, molecular defects, and pathway choice. We also discuss the synthetic lethal effect and acquired resistance to PARP inhibitors. X-ray repair cross-complementing protein 1 (XRCC1), which are recruited at the SSB site in the BER process. However, in the presence of a PARP inhibitor, PARylation is inhibited by PARP-1 activity trapping. 18 The unrepaired damaged DNA encounters the replication fork during replication in S-phase. The collision causes the fork to stall and makes a DSB. 19 In general, DSB induced by DNA-damaging agents has two DNA ends; however, DSB generated through replication fork stalling has only one DNA end, called seDSB ( Figure 1 ).
Double-strand break could be a severe threat to genomic stability and must be corrected. Moreover, unlike two-ended DSB, seDSB needs to be repaired by a more limited pathway to avoid genomic instability and cell lethality. 20 Then, F I G U R E 1 Poly(ADP-ribose) polymerase (PARP) inhibitor-induced cell fate through double-strand break (DSB) repair pathway choice. Single-ended DSB (seDSB) is generated after PARP inhibitor-induced DNA replication fork collapse during S phase. The DSB end protected by the p53-binding protein 1/Rap1-interacting factor 1 (53BP1-RIF1) complex is repaired by error-prone non-homologous end joining (NHEJ) pathway causing cell death. In contrast, the DSB end released by breast cancer susceptibility gene 1/C-terminal-binding protein interacting protein (BRCA1-CtIP) interaction is resected, leading to the homologous recombination (HR) pathway, resulting in cell survival either the NHEJ process, recruitment of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), X-ray cross-complementation group 4 (XRCC4), and DNA ligase IV (Lig4), 21 starts, or DNA ends are resected (DNA end resection) as an initiating step for HR. Molecular mechanisms regulate each DSB repair pathway ( Figure 1 ).
| DSB REPAIR PATHWAY CHOICE
53BP1, RIF1, CtIP, and BRCA1 play key roles in pathway choice.
53BP1 rapidly participates in repair by surrounding DSB sites after its generation and protects damaged ends from excessive end resection. 22, 23 Then, ataxia telangiectasia mutated kinase (ATM)-dependent phosphorylation of 53BP1 recruits the 53BP1-binding factor RIF1 24 and blocks CtIP-dependent DNA end resection. 25 These steps lead to the NHEJ pathway. By contrast, BRCA1 modulates DSB repair pathway with its antagonistic relationship to 53BP1 and RIF1.
Several studies reported that cyclin-dependent kinase (CDK)-dependent CtIP interaction with BRCA1 is important for promoting end resection and suppression of 53BP1-RIF1 signaling. [26] [27] [28] It was also
shown that BRCA1-induced dephosphorylation of 53BP1 causes RIF1 release from the damaged site and repositioning of 53BP1. 29 In contrast, the mechanism of DNA end resection suppression by 53BP1-RIF1 activity is consistent with a report that loss of BRCA1
decelerates CtIP-dependent DNA end resection. 30 Therefore, dysfunction of this process would allow MRE11-induced endonuclease activity to be an initiation step 31 such that CtIP-BRCA1 signaling directs the repair pathway from NHEJ to HR. 32, 33 Also, the number of replication protein A (RPA) foci resections is reduced in the absence of BRCA1 but is still moderate compared to when CtIP is depleted. 29 These findings indicate that CtIP-dependent end resection is available even when BRCA1 is not present. 34 Loss of BRCA1 directs repair to the NHEJ pathway but may not induce a strong inhibition of end resection. In summary, CtIP-BRCA1 and 53BP1-RIF1 regulate each pathway during S/G2 phases ( Figure 2A ) but the detailed mechanisms need to be further investigated.
| PARP INHIBITOR-INDUCED SYNTHETIC LE TH ALITY
Breast cancer susceptibility gene 1/2-mutated cancer cells respond well to Poly(ADP-ribose) polymerase (PARP) inhibitors through synthetic lethality. 7, 8 Poly(ADP-ribose) polymerase inhibitor-induced cell cycle-dependent seDSB could be repaired by HR through the same pathway selection mechanism in the S/G2 phase. Although cells
require NHEJ for two-ended DSB repair to survive, 35 it causes chromosomal aberration, genomic instability in PARP inhibitor-treated cells, and cell death because seDSB has no other DNA end that can be correctly ligated. 36 Therefore, stalled replication fork-induced F I G U R E 2 Mechanisms of synthetic lethality to poly(ADP-ribose) polymerase (PARP) inhibitor in breast cancer susceptibility gene 1/2 (BRCA1/2)-deficient cells through double-strand break (DSB) repair and ensuing pathways during S/G2 phase. PARP inhibitor-induced cell fate analyzed in (A) wild-type (WT), (B) BRCA1-deficient, and (C) BRCA2-deficient cells. 53BP1, p53-binding protein 1; CDK, cyclin-dependent kinase; CtIP, C-terminal-binding protein interacting protein; DNA-PKcs, DNA-dependent protein kinase catalytic subunit; HR, homologous recombination; Lig4, DNA ligase IV; NHEJ, non-homologous end joining; RIF1, Rap1-interacting factor 1 seDSB needs to be repaired by HR (Figures 1, 2A) . Both BRCA1 and BRCA2 are known to play critical roles in the HR pathway. Their roles in synthetic lethality will be discussed in the context of other molecules. In addition, the mechanism of synthetic lethality in BRCA1/2-mutated cells based on the DSB repair pathway models will be explained.
Breast cancer susceptibility gene 1, a key player in DSB repair, directs HR with CtIP by promoting DNA end resection by suppression of the 53BP1-RIF1 pathway. 29, 32 The presence of BRCA1 leads to dysfunctional NHEJ and functional HR in DSB repair. It could also help maintain genomic stability by preventing error-prone repair of accidentally generated seDSB. 37 Conversely, loss of BRCA1-induced 53BP1-RIF1 signaling restoration directs the repair pathway to NHEJ and causes RIF1-dependent partial suppression of end resection.
BRCA1 also recruits Rad51 onto the resected DNA strand by replacing RPA and colocalizing with Rad51 and BRCA2 to activate HR 38, 39 such that it cannot function in BRCA1-deficient cells. Therefore, Consequently, impairment of replication fork protection as a result of BRCA1 or BRCA2 dysfunction is considered to be an important mechanism for synthetic lethality by PARP inhibition. Figure 3A) . Markedly, 53BP1 rescues proliferation defects in BRCA1 but not in BRCA2-deficient mouse embryonic fibroblasts (MEF). 58 Both BRCA1 and BRCA2 defects in cells tend to induce spontaneous replication stress because of lower HR activity. However, BRCA2 is an indispensable factor in the HR process after end resection. Therefore, the repair pathway shift through 53BP1 loss may not affect cell survival in BRCA2-deficient cells ( Figure 3B ).
| Additional resistance mechanisms to PARP inhibitor therapy
To date, in addition to secondary mutation and loss of 53BP1 function, different mechanisms underlying PARP inhibitor resistance have been described and resistance mechanisms can be divided into three groups ( Table 1 ). The first group, "restoration of homologous recombination" includes demethylation of the BRCA1 promoter, 61 the aforementioned secondary mutation of BRCA1/2, 50-57 and loss of HR suppression factors such as 53BP1. [58] [59] [60] [62] [63] [64] The second contains acquisition of replication fork protection. [65] [66] [67] [68] [69] The third has the P-glycoprotein (also known as multidrug resistance protein Therefore, the clinical strategies to overcome the acquired resistance 
